Daclizumab Use in Patients With Pediatric Multiple Sclerosis
Authors:
- Jan-Mendelt TillemaJTJan-Mendelt Tillema
- Annika M. CiliaxACAnnika M. Ciliax
- Charles R. G. GuttmannCGCharles R. G. Guttmann
- Tanuja ChitnisTCTanuja Chitnis
Open Access
- 1 January 2012
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (1) , 78-81
Abstract
BackgroundDaclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease aKeywords
This publication has 16 references indexed in Scilit:
- Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple SclerosisArchives of Neurology, 2011
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaThe Lancet Neurology, 2010
- Cyclophosphamide therapy in pediatric multiple sclerosisNeurology, 2009
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009
- Natalizumab Use in Pediatric Multiple SclerosisArchives of Neurology, 2008
- Daclizumab phase II trial in relapsing and remitting multiple sclerosisNeurology, 2007
- Consensus definitions proposed for pediatric multiple sclerosis and related disordersNeurology, 2007
- Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative StudyNeurological Sciences, 2005
- Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibodyAnnals of Neurology, 2004